Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment
International Journal of Molecular Sciences · 26.07.2023 · 24 (15) · 11939
DOI: 10.3390/ijms241511939 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 26.07.2023. Verfasst von Hisahide Nishio und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Rehabilitation, Kobe Gakuin University, 518 Arise, Ikawadani-cho, Nishi-ku, Kobe 651-2180, Japan. Hauptthemen laut MEDLINE: Muscular Atrophy, Spinal. Die Arbeit wurde bisher 162-mal zitiert (Crossref) und nennt 187 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science and Technology, Ministry of Education, Culture, Sports, Science and Technology, Japan.
Abstract (Originalsprache)
Spinal muscular atrophy (SMA) is a lower motor neuron disease with autosomal recessive inheritance. The first cases of SMA were reported by Werdnig in 1891. Although the phenotypic variation of SMA led to controversy regarding the clinical entity of the disease, the genetic homogeneity of SMA was proved in 1990. Five years later, in 1995, the gene responsible for SMA, SMN1, was identified. Genetic testing of SMN1 has enabled precise epidemiological studies, revealing that SMA occurs in 1 of 10,000 to 20,000 live births and that more than 95% of affected patients are homozygous for SMN1 deletion. In 2016, nusinersen was the first drug approved for treatment of SMA in the United States. Two other drugs were subsequently approved: onasemnogene abeparvovec and risdiplam. Clinical trials with these drugs targeting patients with pre-symptomatic SMA (those who were diagnosed by genetic testing but showed no symptoms) revealed that such patients could achieve the milestones of independent sitting and/or walking. Following the great success of these trials, population-based newborn screening programs for SMA (more precisely, SMN1-deleted SMA) have been increasingly implemented worldwide. Early detection by newborn screening and early treatment with new drugs are expected to soon become the standards in the field of SMA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Rehabilitation, Kobe Gakuin University, 518 Arise, Ikawadani-cho, Nishi-ku, Kobe 651-2180, Japan.
- Laboratory of Molecular and Biochemical Research, Biomedical Research Core Facilities, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
- Department of Neurology, National Hospital Organization Osaka Toneyama Medical Center, 5-1-1 Toneyama, Toyonaka 560-8552, Japan.
- Department of Pediatrics, Ehime Prefectural Imabari Hospital, 4-5-5 Ishi-cho, Imabari 794-0006, Japan.
- Department of Pediatrics, Hyogo Medical University, 1-1 Mukogawacho, Nishinomiya 663-8501, Japan.
- Organization for Research Initiative and Promotion, Research Initiative Center, Tottori University, 86 Nishi-cho, Yonago 683-8503, Japan.
ORCID-Profile: Hisahide Nishio, Emma Tabe Eko Niba, Kentaro Okamoto, Yasuhiro Takeshima
Förderung
- Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Education, Culture, Sports, Science and Technology, Japan
Zitieren
APA
Nishio, H., Niba, E. T. E., Saito, T., Okamoto, K., Takeshima, Y., & Awano, H. (2023). Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment. International Journal of Molecular Sciences, 24(15), 11939. https://doi.org/10.3390/ijms241511939
Vancouver
Nishio H, Niba ETE, Saito T, Okamoto K, Takeshima Y, Awano H. Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment. International Journal of Molecular Sciences. 2023;24(15):11939. doi:10.3390/ijms241511939
BibTeX
@article{Nishio2023,
author = {Nishio, Hisahide and Niba, Emma Tabe Eko and Saito, Toshio and Okamoto, Kentaro and Takeshima, Yasuhiro and Awano, Hiroyuki},
title = {Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {15},
pages = {11939},
doi = {10.3390/ijms241511939}
}
EUVIMED